Program and Abstracts from the Canadian Digestive Diseases Week 2016

Table 50

Patient demographics and clinical outcomes.

	Early Anti-TNF	Late Anti-TNF
(%)	57 (49.6)	58 (50.4)
Infliximab (%)	40 (70.2)	38 (65.5)	0.59
Adalimumab (%)	17 (29.8)	20 (34.5)
Median time to anti-TNF (weeks, IQR)	38.1 (23.3–91.0)	414.0 (254.0–561.3)	<0.001
Active or former smoker (%)	11 (19.3)	15 (25.9)	0.76
Pancolitis (%)	43 (75.4)	40 (69.0)	0.44
Endoscopic mayo score at anti-TNF (mean, ±SD)	2.46 (±0.66)	1.86 (±0.67)	<0.001
Colectomy (%)	10 (17.5)	5 (8.6)	0.16
UC-related hospitalization	25 (43.9)	16 (27.6)	0.07
Clinical loss of response	28 (49.1)	34 (58.6)	0.31